[go: up one dir, main page]

AU2001278626A1 - Tetrahydropyran derivatives as nk-1 receptor antagonists - Google Patents

Tetrahydropyran derivatives as nk-1 receptor antagonists

Info

Publication number
AU2001278626A1
AU2001278626A1 AU2001278626A AU7862601A AU2001278626A1 AU 2001278626 A1 AU2001278626 A1 AU 2001278626A1 AU 2001278626 A AU2001278626 A AU 2001278626A AU 7862601 A AU7862601 A AU 7862601A AU 2001278626 A1 AU2001278626 A1 AU 2001278626A1
Authority
AU
Australia
Prior art keywords
receptor antagonists
tetrahydropyran derivatives
tetrahydropyran
derivatives
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278626A
Inventor
Jose Luis Castro Pineiro
Simon Neil Owen
Eileen Mary Seward
Christopher John Swain
Brian John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of AU2001278626A1 publication Critical patent/AU2001278626A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001278626A 2000-08-22 2001-08-17 Tetrahydropyran derivatives as nk-1 receptor antagonists Abandoned AU2001278626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0020721.7A GB0020721D0 (en) 2000-08-22 2000-08-22 Therapeutic agents
GB0020721 2000-08-22
PCT/GB2001/003685 WO2002016343A1 (en) 2000-08-22 2001-08-17 Tetrahydropyran derivatives as nk-1 receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001278626A1 true AU2001278626A1 (en) 2002-03-04

Family

ID=9898111

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001279950A Abandoned AU2001279950A1 (en) 2000-08-22 2001-08-17 Tetrahydropyran derivatives as nk-1 receptor antagonists
AU2001278626A Abandoned AU2001278626A1 (en) 2000-08-22 2001-08-17 Tetrahydropyran derivatives as nk-1 receptor antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001279950A Abandoned AU2001279950A1 (en) 2000-08-22 2001-08-17 Tetrahydropyran derivatives as nk-1 receptor antagonists

Country Status (6)

Country Link
US (1) US6489343B2 (en)
AU (2) AU2001279950A1 (en)
GB (1) GB0020721D0 (en)
JO (1) JO2231B1 (en)
PE (1) PE20020436A1 (en)
WO (2) WO2002016343A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064223A1 (en) * 2000-02-29 2001-09-07 Merck Frosst Canada & Co. Method for treating or preventing depression
GB0121874D0 (en) * 2001-09-10 2001-10-31 Merck Sharp & Dohme Therapeutic agents
GB0217068D0 (en) * 2002-07-23 2002-08-28 Merck Sharp & Dohme Therapeutic agents
US7393858B2 (en) 2003-03-07 2008-07-01 Merck Sharp & Dohme Ltd. Tetrahydropyran compounds as tachykinin antagonists
CA2588993A1 (en) * 2004-11-22 2006-06-01 Mallinckrodt Inc. Process for the purification of benzphetamine hydrochloride
DE602005014138D1 (en) * 2004-11-30 2009-06-04 Mallinckrodt Inc METHOD FOR CRYSTALLIZING BENZPHETAMINE
JPWO2006115188A1 (en) * 2005-04-22 2008-12-18 第一三共株式会社 Heterocyclic compounds
CN101180285B (en) * 2005-05-25 2013-01-09 默克专利股份有限公司 Formyltetrahydropyrans, method for the production thereof and use thereof in the production of liquid crystal compounds
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
FR3002733B1 (en) 2013-03-04 2015-08-14 Servier Lab NOVEL SALT OF THE ABEXINOSTAT, THE CRYSTALLINE FORM ASSOCIATED WITH THEM, THE PROCESS FOR PREPARING THEM AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SG10201901916WA (en) 2014-09-03 2019-04-29 Pharmacyclics Llc Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
PT3725786T (en) * 2017-12-13 2023-10-17 Genfleet Therapeutics Shanghai Inc Crystal form and salt form of tgf-bri inhibitor and preparation method therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301920D0 (en) 1993-02-01 1993-03-17 Foundation For Ethnobiology Th Polycetylenes
ATE278687T1 (en) * 1993-12-29 2004-10-15 Merck Sharp & Dohme SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
WO1999064006A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
CA2334609A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
CO5150225A1 (en) 1999-03-19 2002-04-29 Merck Sharp & Dohme DERIVATIVES OF TETRAHYDROPIRANE AND ITS USE AS THERAPEUTIC AGENTS

Also Published As

Publication number Publication date
PE20020436A1 (en) 2002-06-14
JO2231B1 (en) 2004-10-07
GB0020721D0 (en) 2000-10-11
US6489343B2 (en) 2002-12-03
AU2001279950A1 (en) 2002-03-04
WO2002016343A1 (en) 2002-02-28
US20020035132A1 (en) 2002-03-21
WO2002016344A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
EP1349839B8 (en) Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
AU2001269876A1 (en) Heteroarylalkanoic acids as integrin receptor antagonists
AU2001255798A1 (en) Glucagon antagonists
AU2001264657A1 (en) Crf receptor antagonists
AU2001231664A1 (en) Indol-3-yl derivatives
AU2001273032A1 (en) Cytokine receptor zcytor17
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
AU2001278626A1 (en) Tetrahydropyran derivatives as nk-1 receptor antagonists
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2541000A (en) Beta-phenylalanine derivatives as integrin antagonists
AU2441801A (en) Urotensin-ii receptor antagonists
AU2001245724A1 (en) Il-8 receptor antagonists
AU2001240021A1 (en) Diazafluorenone il-8 receptor antagonists
AU2002216079A1 (en) Bombesin receptor antagonists
AU2002226048A1 (en) Urotensin-ii receptor antagonists
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU2002347552A1 (en) 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002239506A1 (en) Urotensin-ii receptor antagonists
AU2001243351A1 (en) Il-8 receptor antagonists
AU2673201A (en) Alpha-arylethylpiperazine derivatives as neurokinin antagonists
AU2001263288A1 (en) Crf receptor antagonists
AU2001249573A1 (en) Chemokine receptor antagonists
AU2002217095A1 (en) Bombesin receptor antagonists